4.6 Article

Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity?

期刊

CANCER IMMUNOLOGY RESEARCH
卷 9, 期 1, 页码 2-7

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-20-0525

关键词

-

资金

  1. NIH [CA240955]
  2. Charles A. King Trust Fellowship
  3. U.S. Department of Defense Breast Cancer Breakthrough Fellowship

向作者/读者索取更多资源

The research highlights the role of gasdermin-mediated inflammatory death in promoting antitumor immunity and converting immune cell killing to inflammatory pyroptosis. This may enhance the effectiveness of immunotherapy but also increase therapy-related toxicity, requiring further study to understand its regulation and potential therapeutic applications.
The impressive success of current cancer immunotherapy in some patients but lack of effectiveness in most patients suggests that additional strategies to promote antitumor immunity are needed. How cancer cells die, whether spontaneously or in response to therapeutic intervention, has a profound effect on the type of immune response mobilized. Here, we review research that highlights a previously unappreciated role of gasdermin-mediated inflammatory death (pyroptosis) to promote antitumor immunity and identifies gasdermin E as a tumor suppressor. Immune elimination of tumor cells by natural killer cells and cytotoxic T lymphocytes, which is the final key event in antitumor immunity, was previously thought to be noninflammatory. The research shows that gasdermin expression in tumor cells converts immune cell-mediated killing to inflammatory pyroptosis when cell death-inducing granzymes directly cleave and activate gasdermins. Granzyme B cleaves gasdermin E, and granzyme A cleaves gasdermin B. The data suggest the potential to harness pyroptosis in the tumor to ignite an effective immune response to immunologically cold tumors. Gasdermin expression also augments toxicity of cancer therapy-gasdemiin E expression by B-cell leukemias and lymphomas is a root cause of chimeric antigen receptor (CAR) T-cell cytokine storm, and its expression in normal tissues promotes the toxicity of chemotherapeutic drugs. Even though our knowledge about the role of pyroptosis in cancer is growing, there is still a lot to learn-what activates it, how it is regulated, when it is beneficial, and how it can be harnessed therapeutically to improve cancer immunotherapy or reduce therapy-related toxicity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据